(PRWEB) November 21, 2013
Translational Sciences Inc. announces that StromAb is in production on Phase I Clinical Trials. Production began after completing highly successful pre-clinical development studies showing exceptional efficacy and safety in multiple disease models.
StromAb is a first-in-class antibody providing immediate safe dissolution of ACUTE blood clots that cause > 2 million cases of ischemic stroke, venous thrombosis, pulmonary embolism, heart attack and acute peripheral vascular ischemia in the U.S. alone.
Translational Sciences Inc. holds exclusive licensing rights with Massachusetts General Hospital & Harvard University.
Distinct from existing agents or agents in development: StromAb occupies a different therapeutic space, than anticoagulants (e.g., heparins, or direct thrombin or factor Xa inhibitors etc.). StromAb rapidly dissolves clots in ACUTE cardiovascular diseases; anticoagulants inhibit blood clot formation but do not dissolve clots.
However, StromAb is also compatible with anticoagulants in the therapeutic process.
StromAb was selected by NIH for therapeutic development grants. StromAb is supported by multiple patents and patent actions.
Translational Sciences is currently exploring partnerships for future clinical trials.
Experts Have Commented:
“The striking preclinical profile of StroMAb .…predicts both a significant improvement in efficacy and major reductions in risk….could revolutionize the treatment of ischemic stroke.”
- “This is a highly significant project that addresses the most important unmet medical need for safe drugs to treat acute thrombotic diseases with poor prognosis (stroke, heart attack, pulmonary embolism, arterial thrombosis)."
- “These antibodies have the potential to dramatically change the course of treatment of thromboembolic stroke and other ischemic diseases.”
Translational Sciences, Inc. is a privately held biopharmaceutical company that translates scientific insights into first-in-class, biologic agents for cardiovascular diseases.
Interested parties may contact Translational Sciences at 901-274-4506 or email David Pedersen, dpedersen(at)translationalsciences(dot)com
Read the full story at http://www.prweb.com/releases/2013/11/prweb11351177.htm.
Related biology technology :1
Copyright©2012 Vocus, Inc.
All rights reserved
. TesoRx and CoreRx Announce Joint Venture to Manufacture First-in-Class Oral Testosterone Drug2
. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain3
. Labome: The Gateway to the Perfect Antibody -- Labome Antibody Review Database Has Now Reached 10,000 Peer-Reviewed Formal Publications4
. Sorrento Therapeutics Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit5
. Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment6
. Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech7
. GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research8
. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer9
. Goodwin Biotechnology and Coldstream Laboratories Announce a Collaboration to Develop and Manufacture Cytotoxic Antibody Drug Conjugates10
. Scripps Research Institute Scientists Find Antibody that Transforms Bone Marrow Stem Cells Directly into Brain Cells11
. Antibody Technologies and Attrition Rates -- an industry analysis 2013